FBLG News & Events

FibroBiologics announced a strategic expansion of its fibroblast-based platform to target Hantavirus. Building on existing preclinical work in treating acute respiratory distress syndrome, the major cause of lethality in COVID-19 patients, FibroBiologics is expanding its therapeutic platform to encompass Hantavirus pulmonary syndrome, which causes similar terminal lung damage and inflammatory cascade as severe COVID-related ARDS.

FibroBiologics announced preclinical results suggesting that topical treatment with human dermal fibroblast spheroids may reprogram the burn wound environment by dampening harmful inflammation, reshaping immune cell behavior, and reducing markers of scar-forming activity, within eight days of injury. "These preclinical results are an important validation of our strategy to broaden the FibroBiologics wound care platform beyond our core indications. Fibroblasts play an essential role in wound healing, and what we are seeing here suggests they may be uniquely positioned to address the pathological inflammation and scarring that define burn injuries," said Pete O'Heeron, founder and CEO.

FibroBiologics announced the release of the first batch of its CYWC628 drug product to support its Phase 1/2 clinical trial in patients with diabetic foot ulcers. "With the first batch of the CYWC628 drug product released, we are now positioned to begin enrolling patients in our Phase 1/2 DFU trial," said Pete O'Heeron, founder and CEO of FibroBiologics. The drug product was manufactured in accordance with the U.S. Food and Drug Administration's current Good Manufacturing Practices and has successfully passed all required safety and quality testing, enabling its release for clinical use. CYWC628 is an investigational fibroblast-based therapy designed to address diabetic foot ulcers, a chronic condition affecting millions of patients worldwide with limited effective long-term treatment options.